AC Immune Highlights Neurodegenerative Pipeline Progress at AAIC 2026
Event summary
- AC Immune will present three data sets at AAIC 2026 in London, showcasing its Morphomer®-based pipeline for neurodegenerative diseases.
- Key programs include a TDP-43 PET tracer with early human imaging data, a Phase 1 NLRP3 inhibitor, and an alpha-synuclein aggregation inhibitor.
- Presentations span July 12–15, covering diagnostics and drug development sessions.
The big picture
AC Immune’s presentations at AAIC 2026 underscore its focus on precision therapeutics for neurodegenerative diseases, an area with high unmet medical need. The company’s Morphomer® platform positions it as a key player in developing small-molecule therapies and diagnostic tools, though success will depend on translating early-stage data into clinical and commercial outcomes.
What we're watching
- Clinical Validation
- Whether AC Immune’s Morphomer®-based assets can demonstrate sustained efficacy in neurodegenerative disease models.
- Pipeline Momentum
- The pace at which the company advances its biomarker-led therapeutic programs into later-stage trials.
- Strategic Partnerships
- How AAIC 2026 data may influence collaborations with global pharmaceutical companies.